Publications by authors named "D B Jump"

Presenting data from the first phase of a U.K.-based 5-year mixed-methods study, we restart a decade-long conversation into Girls and Gangs and Violence Against Women and Girls (VAWG).

View Article and Find Full Text PDF

Clinical and preclinical studies established that supplementing diets with ω3 polyunsaturated fatty acids (PUFA) can reduce hepatic dysfunction in nonalcoholic steatohepatitis (NASH) but molecular underpinnings of this action were elusive. Herein, we used multi-omic network analysis that unveiled critical molecular pathways involved in ω3 PUFA effects in a preclinical mouse model of western diet induced NASH. Since NASH is a precursor of liver cancer, we also performed meta-analysis of human liver cancer transcriptomes that uncovered betacellulin as a key EGFR-binding protein upregulated in liver cancer and downregulated by ω3 PUFAs in animals and humans with NASH.

View Article and Find Full Text PDF
Article Synopsis
  • - Nonalcoholic fatty liver disease (NAFLD) is a significant global health issue, and understanding its progression could help develop new treatment strategies.
  • - A study on Ldlr-/- mice showed that a western diet (WD) rapidly decreased essential fatty acids (EFAs) and increased markers of inflammation linked to the development of nonalcoholic steatohepatitis (NASH) within just one week.
  • - The research suggests that monitoring and addressing EFA levels early on could potentially reduce the severity of NASH, as hepatic inflammation is closely associated with this condition.
View Article and Find Full Text PDF
Article Synopsis
  • * The study examined male and female mice on a western diet (WD) for either 1 week or 40 weeks, finding that only those on the WD for 40 weeks showed clear signs of nonalcoholic steatohepatitis (NASH), including liver fat accumulation and fibrosis.
  • * RNA sequencing revealed significant changes in gene expression within just 1 week of the WD, indicating early markers of disease linked to inflammation and metabolic syndrome, suggesting that early detection through gene targeting could help prevent disease progression.
View Article and Find Full Text PDF

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic fatty liver disease worldwide, particularly in obese and type 2 diabetic individuals. Currently, there are no therapies for NAFLD that have been approved by the US Food and Drug Administration. Herein, we examine the rationale for using ω3 polyunsaturated fatty acids (PUFAs) in NAFLD therapy.

View Article and Find Full Text PDF